The promise of atypical antipsychotics

References

• Citrome L. New antipsychotic medications: What advantages do they offer? Postgrad Med 1997; 101(2): 207–14
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia. International Suicide Prevention Trial (Inter SePT). Arch Gen Psychiatry 2003; 60(1): 82–91 [Erratum, Arch Gen Psychiatry 2003; 60(7): 735]
   PubMed Web of Science ®Google Scholar
• Citrome L, Bilder RM, Volavka J. Managing treatment-resistant schizophrenia: evidence from randomized clinical trials. J Psychiatr Pract 2002; 8(4): 205–15
   PubMedGoogle Scholar
• Citrome L, Volavka J. Atypical antipsychotics: Revolutionary or incremental advance? Expert Rev Neuratherapeutics 2002; 2(1): 69–88
   PubMedGoogle Scholar
• Hirschfeld RM. The efficacy of atypical antipsychotics in bipolar disorders. J Clin Psychiatry 2003; 64(Suppl 8): 15–21
   Google Scholar
• Stahl SM. Essential psychopharmacology: neuro- scientific basis and practical applications. 2nd ed. Cambridge: Cambridge Univ Press, 2000: 414–25
   Google Scholar
• Volavka J, Czobor P, Sheitman B, et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 2002; 159(2): 255–62 [Erratum, Am J Psychiatry 2002; 159(12): 2132]
   PubMed Web of Science ®Google Scholar
• Bilder RM, Goldman RS, Volavka J, et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 2002; 159(6): 1018–28
   PubMed Web of Science ®Google Scholar
• Citrome L, Volavka J, Czobor P, et al. Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. Psychiatr Serv 2001; 52(11): 1510–4
   PubMed Web of Science ®Google Scholar
• Geddes J, Freeman tie N, Harrison P, et al. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and metaregression analysis. BMJ 2000; 321(7273): 1371–6
   PubMed Web of Science ®Google Scholar
• Rosenheck R, Perlick D, Bingham S, et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 2003; 290(20): 2693–702
   PubMed Web of Science ®Google Scholar
• Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003; 60(6): 553–64
   PubMed Web of Science ®Google Scholar
• Risperdal product information. Physicians' desk reference. 58th ed. Montvale, NJ: Thomson PDR, 2004: 1764–8
   Google Scholar
• McIntyre RS, Trakas K, Lin D, et al. Risk of weight gain associated with antipsychotic treatment: results from the Canadian National Outcomes Measurement Study in Schizophrenia. Can J Psychiatry 2003; 48(10): 689–94
   PubMed Web of Science ®Google Scholar
• Citrome L. The increase in risk of diabetes mellitus from exposure to second generation antipsychotics. Drugs of Today 2004; 40(5): 445–64
   PubMedGoogle Scholar
• Volavka J, Czobor P, Cooper TB, et al. Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychiatry 2004; 65(1): 57–61
   PubMed Web of Science ®Google Scholar
• Kinon BJ, Basson BR, Gilmore JA, et al. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 2001; 62(2): 92–100
   PubMed Web of Science ®Google Scholar
• Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2003 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2003; 27(Suppl 2): S10–3
   Google Scholar
• American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27(2): 596–601
   PubMed Web of Science ®Google Scholar
• Geodon product information. Physicians' desk reference. 58th ed. Montvale, NJ: Thomson PDR, 2004: 2597–603
   Google Scholar
• Glassman AH, Bigger JT Jr. Drs Glassman and Bigger reply. (Letter) Am J Psychiatry 2002; 159(6): 1064
   Google Scholar
• Citrome L, Volavka J. Optimal dosing of atypical antipsychotics in adults: a review of the current evidence. Harv Rev Psychiatry 2002; 10(5): 280–91
   PubMed Web of Science ®Google Scholar
• Citrome L, Jaffe A, Levine J. Dosing of second-generation antipsychotics in a large state hospital system. Presented at the 157th American Psychiatric Association Annual Meeting, May 1–6, 2004, New York
   Google Scholar
• Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003; 60(11): 1079–88 [Erratum, Arch Gen Psychiatry 2004; 61(2): 176]
   PubMed Web of Science ®Google Scholar
• Manning JS, Haykal RF, Connor PD, et al. On the nature of depressive and anxious states in a family practice setting: the high prevalence of bipolar II and related disorders in a cohort followed longitudinally. Compr Psychiatry 1997; 38(2): 102–8
   PubMed Web of Science ®Google Scholar
• Citrome L. Atypical antipsychotics for acute agitation: new intramuscular options offer advantages. Postgrad Med 2002; 112(6): 85–96
   Web of Science ®Google Scholar
• Kane JM, Eerdekens M, Lindenmayer JP, et al. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003; 160(6): 1125–32
   PubMed Web of Science ®Google Scholar
• Marder SR, Conley R, Ereshefsky L, et al. Clinical guidelines: dosing and switching strategies for long-acting risperidone. J Clin Psychiatry 2003; 64(Suppl 16): 41–6
   PubMedGoogle Scholar
• Citrome L, Blonde L, Dama tarca C. Metabolic issues in patients with severe mental illness. South Med J (in press)
   Google Scholar